[1]侯敏娜,侯少平,逯莉,等.基于整合药理学平台的当归补血汤治疗贫血分子作用机制研究[J].西部中医药,2023,36(11):8-13.[doi:10.12174/j.issn.2096-9600.2023.11.02]
　HOU Minna,HOU Shaoping,LU Li,et al.Study on the Molecular Mechanism of Danggui Buxue Tang in Treating Anemia Based on TCMIP[J].Western Journal of Traditional Chinese Medicine,2023,36(11):8-13.[doi:10.12174/j.issn.2096-9600.2023.11.02]
点击复制

基于整合药理学平台的当归补血汤治疗贫血分子作用机制研究
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年11期
页码:
8-13
栏目:
出版日期:
2023-11-15

文章信息/Info

Title:
Study on the Molecular Mechanism of Danggui Buxue Tang in Treating Anemia Based on TCMIP
作者:
侯敏娜, 侯少平, 逯莉, 王飞娟, 许海燕, 刘艳红
陕西国际商贸学院，陕西 咸阳 712046
Author(s):
HOU Minna, HOU Shaoping, LU Li, WANG Feijuan, XU Haiyan, LIU Yanhong
Shaanxi Institute of International Trade & Commerce, Xianyang 712046, China
关键词:
贫血; 当归补血汤; 分子作用机制; 整合药理学
Keywords:
anemia; molecular mechanism; integrative pharmacology
分类号:
R259
DOI:
10.12174/j.issn.2096-9600.2023.11.02
文献标志码:
A
摘要:
目的借助整合药理学平台研究当归补血汤治疗贫血的分子作用机制。 方法依托中医药整合药理学平台（integrative pharmacology-based research platform of traditional Chinese medicine，TCMIP）V2.0，构建当归补血汤治疗贫血的“方剂-中药材-成分-疾病-靶标-通路”多维关系网络图，预测其治疗贫血疾病的关键靶标和作用通路，揭示其分子作用机制。 结果当归补血汤中与贫血疾病相关的化学成分包括谷甾醇、叶酸、华良姜素、豆甾醇、琥珀酸、叶酸、癸二酸、壬二酸8种，核心靶标176个，共有靶标9个；前20位核心靶标和通路中多数靶标与癌性贫血发生有关，如Akt1、CCND1、ABL1、EPOR、GATA1、SMAD4等可能通过细胞增殖正调节、细胞增长负调节、蛋白激酶b信号蛋白正调节、细胞分化等通路起抑制癌细胞增殖、增长、分化及凋亡等作用；而NFKB1、HSP90AA1、TFRC、TF、NDUFV1、NDUFS1等靶标可能通过细胞因子介导的信号通路、Nf-kappab转录因子正调节、线粒体呼吸链组装、红细胞分化、促红细胞生成素介导信号通路、肽丝氨酸磷酸化正调节等途径，以提高免疫力、补充营养、消除炎症等方式治疗缺铁性贫血、炎性贫血、心脑缺血、糖尿病并发症及改善营养不良性等的贫血。 结论当归补血汤可通过多靶点、多通路治疗缺铁性贫血、心脑缺血、癌性贫血、炎性贫血、营养不良性贫血及糖尿病、高脂血症等引起的贫血。
Abstract:
ObjectiveTo study the molecular mechanism of Danggui Buxue Tang in the treatment of anemia based on TCMIP. MethodsBased on TCMIP V2.0, the multi-dimensional relationship network diagram of "prescription-Chinese medicine-composition-disease-target-pathway" was constructed to predict the key targets and action pathways of Danggui Buxue Tang in treating anemia, and reveal its molecular mechanism of action. ResultsEight kinds of anemia-related chemical components in Danggui Buxue Tang were sitosterol, 3-hydroxycoumarin folic acid, kumatakenin, stigmasterol, succinic acid, folic acid, sebacic acid and azelaic acid, there were 176 core targets and nine common targets; the top 20 core targets and most of the targets in the pathways were related to cancer-related anemia, for instance, the targets of Akt1, CCND1, ABL1, EPOR, GATA1, SMAD4 and others could inhibit the proliferation, growth, differentiation and apoptosis of cancer cells possibly through positive regulation of cell proliferation, negative regulation of cell growth, positive regulation of protein kinase B signal protein and cellular differentiation; while targets including NFKB1, HSP90AA1, TFRC, TF, NDUFV1, NDUFS1, etc, could treat iron deficiency anaemia, inflammatory anaemia, cardiac and cerebral ischaemia, diabetic complications and malnutritional anaemia by boosting immunity, supplementation and eliminating inflammation, possibly through cytokine-mediated signaling pathway, positive regulation of Nf-kappab transcription factor, mitochondrial chain assembly, red blood cell differentiation, hemopoietin-mediated signaling pathway, positive regulation of peptide serine phosphorylation, etc. ConclusionDanggui Buxue Tang could be used to treat iron deficiency anaemia, cardiac and cerebral ischaemia, cancerous anemia, inflammatory anaemia, malnutritional anaemia, and anaemia induced by diabetes and hyperlipemia.

相似文献/References:

[1]石红梅.人参归脾丸对缺铁性贫血患者HB、RBC、HCT的影响[J].西部中医药,2013,26(03):80.
　SHI Hongmei.Effect of RenShen GuiPiW an on HGB, RBC and HCT of Patients with Iron-deficiency Anemia[J].Western Journal of Traditional Chinese Medicine,2013,26(11):80.
[2]连琯,史晓伟.当归补血汤合金水宝治疗早期糖尿病肾病16例临床观察[J].西部中医药,2013,26(06):68.
　LIAN Guan,SHI Xiaowei.Clinical Observation on DangGui BuXueTang and JinShuiBao in Treating 16 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(11):68.
[3]黄邦荣,张东鹏△.裴正学教授治疗再生障碍性贫血的经验[J].西部中医药,2013,26(07):37.
　HUANG Bangrong,ZHANG Dongpeng.Professor PEI Zhengxue′s Experience of Treating Aplastic Anemia[J].Western Journal of Traditional Chinese Medicine,2013,26(11):37.
[4]夏小军,段赟.中医药治疗自身免疫性溶血性贫血的思路与方法[J].西部中医药,2016,29(02):41.
　XIA Xiaojun,DUAN Yun.Thinking and Methods of TCM in the Treatment for Autoimmune Hemolytic Anemia[J].Western Journal of Traditional Chinese Medicine,2016,29(11):41.
[5]曾翠青,吴东明,段小军,等.足三里穴位注射重组人促红素治疗肾性贫血疗效观察[J].西部中医药,2022,35(09):126.[doi:10.12174/j.issn.2096-9600.2022.09.26]
　ZENG Cuiqing,WU Dongming,DUAN Xiaojun,et al.Clinical Observation on Zusanli Acupoint Injection of Recombinant Human Erythropoietin Injection in the Treatment of Renal Anemia[J].Western Journal of Traditional Chinese Medicine,2022,35(11):126.[doi:10.12174/j.issn.2096-9600.2022.09.26]
[6]王玥,栗枭杰,吴朝旭,等.贫血对晚期胃癌患者预后及生活质量的影响[J].西部中医药,2023,36(11):101.[doi:10.12174/j.issn.2096-9600.2023.11.22]
　WANG Yue,LI Xiaojie,WU Chaoxu,et al.Influence of Anemia on the Prognosis and Quality of Life of Patients with Advanced Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2023,36(11):101.[doi:10.12174/j.issn.2096-9600.2023.11.22]

备注/Memo

备注/Memo:
侯敏娜（1981—），女，硕士学位，副教授。研究方向：中药药效物质基础研究。国家科技部重大新药创制科技重大专项 （2018ZX09721005-009-013）；陕西省重点研发计划（2020SF-323）；陕西国际商贸学院中药质量标志物创新团队（SSY18TD02）；陕西省大学生创新创业训练计划项目（S202013123043，S202013123037，S202013123045，S202013123023）；陕西省教育厅2021年度青年创新团队科研计划项目（21JP012）。
更新日期/Last Update: 2023-11-15